Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL! Still way shy of $2.10 NASDAQ keeps posting about. This story just gets better and better.
Nice! A friend recommended RobinHood for big exchange trading. No options or OTC available yet, but there are no trading commissions. Anyone try them? I was planning to open an acct later this month, but thought I'd ping the board first.
Then I assume you see the circular nature of this argument. They are paid in stock because the company can't cover typical SG&A. Stock can't be sold or stock would plummet further. Recent Form 4's only signify the company doesn't have enough cash to go around.
They can be but highly unlikely that it isn't worth arguing. Payments were made in accordance to the agreements. Elite would win in the end in this case or just settle, however, if the tech works out, that is the last step Puracap would make with a potential huge partner.
They also have cash to pay employees.
Yes and no. They also know that if they sell current shareholders will unleash a violent selling storm cratering the stock well below current status as any remaining trust will be quickly eroded.
That is nothing but timing.
No, that is just the annual agreement of shares being paid.
Yes, there are many variables. It comes down to whether the company is bought out at higher than $2.10/ share. If not, it means the dilution was for naught, since per the CEO, that was the most probable value a couple years back.
Yes, I see - buyout is at a buck. This is less than half the value per share provided 2 years ago at the company valuation. All the dilution has been more detrimental to the share value than the studies & pipeline growth over the last two years. There is pure trust in the CEO. LOL
Are you saying the value has gone down from the most probable value of $2.10 from a couple years ago?
Except CEO said the study would be started in Q1. Future tense was used during the call since it hadn't started yet in February. SequestOx will be refiled during latter backhalf of year.
Not getting any smaller either with the ongoing dilution. Good news is that it did slow a bit last quarter, but I think that may just be a blip.
It was a few years ago. How much longer are you expecting to wait? It could also be a dud.
"Good chance" the other day. Like a politician. Covering tracks after being burned a few times.
What makes you so sure? He hid the SequestOx Tmax issue from investors. I personally don't think he did.
What are you expecting the sales split to be when we do find a partner? I model out 20% margin on manufacturing and about 8% on sales. What assumptions are you using? 25% for sales partner alone seems a little low.
Great commentary on many levels. As always, much appreciated.
Didn't FDA approve Troxyca with supposed manufacturing issues? Hmmm...
Please explain how the market says otherwise? Market has been doing nothing positive for Elite for the past several months. Unless not hitting the 52-week low yet is seen as a positive?
Share count doubling is only fact that has been posted for months.
The 10 degree windchill in Minneapolis today was just as balmy.
So does 6-8 months time without the dilution.
That defeats any logic. A 10 million dollar trade for 10% of the company. If tech I really is worth billions such a move would be among the most asinine moves in history, but I wouldn't be surprised.
We all have different opportunities on our radar along with varying risk levels. There are lots of better plays right now as ELTP will be idle at best for a while. Best of luck.
Let's see. How many ADT approvals have they received? And how many FDA rejections? 1-0 rejections are winning.
So why would the CEO of a potential "multi-billion" company sell 10% of the company for a mere 10 million dollars? I didn't think he would pull such a stupid stunt.
They dilute. Every. Single. Quarter. Subsequent events on 10Q showed more dilution. CEO stated they needed more funding. In all reality, there is absolutely nothing that signals that the company is not diluting.
Dilution doesn't care who is holding a long position.
The FDA has given them the green light in the past. Just to help you clarify a path forward does not equal approval.
Hitting the 0.12's. Wow! Didn't think we'd see this. Edging against 52-week low. Saw big seller of 400K earlier. Someone is either ditching their position or CEO is cramming in more dilution. Probably both.
Shows the impact of constant dilution. Locked in downwards channel until the dilution stops. We'll see what happens in April when the LPC deal terminates.
Let's wait for the results. Big egos & wild assumptions didn't help push it through 2 years ago.
As of today, an unsolidified agreement with Puracap tells much more. We'll see in a few months with the results from the fed BE studies and how they pan out.
NASDAQ regarding your private message that's "Nam and I are loaded to the brim". I am interested in fair & balanced dialogue so we can all make the best decisions. Investor's positions do not sway me unless CEO starts selling.
I agree with your thought. That could very well be the case. I think Nasrat's situation is akin to an early investor with too much skin in the game - emotions cloud judgment. Waters are muddied and the best decisions aren't made. That is what I see here.
I am surprised there hasn't been an upfront cash deal for a future partnership. There is something I am missing. If the tech has such amazing potential who wouldn't want to partner with Elite? Something isn't passing the smell test quarter after quarter.
Highly undervalued on generics alone? Financials say it differently. 20% margins are nothing to write home about. I give you credit as you are right on the other points and it is the conglomerate of all these that have led to the lack of faith in the CEO to execute in the near term to avoid the need for significant dilution.
Well, a year ago in May the pps was sitting at 0.38 and as the year progressed it moved to 0.20, then to 0.15 and now we struggle to maintain 0.135. And yes, we are much closer to the year low than we have been for months. Lack of confidence in ability to execute mixed with dilution risk is a terrible combination. Once again, mgmt drives share price south from the conference call. At least there is consistency here.
There was little dilution during Q3, again some more listed under subsequent events in 10Q after the end of the quarter. In the conference call CEO stated the company needs to raise more funds, but whether he uses the remainder of LPC deal before it expires is the question.